As an alternative method, the permanent removal of PD-1 using genome editing (e.g., via CRISPR/Cas9) is considered, although knockout of PD-1 in therapeutic T cells carries high risks such as the development of tumor cells associated with genotoxicity [7]. The gene discussed is PDCD1; the disease is neoplasm.